Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Notes Payables (2016 - 2018)

Lisata Therapeutics filings provide 9 years of Notes Payables readings, the most recent being $23289.0 for Q2 2018.

  • For the quarter ending Q2 2018, Notes Payables fell 96.12% year-over-year to $23289.0, compared with a TTM value of $23289.0 through Jun 2018, down 96.12%, and an annual FY2017 reading of $159000.0, down 77.29% over the prior year.
  • Notes Payables hit $23289.0 in Q2 2018 for Lisata Therapeutics, down from $100000.0 in the prior quarter.
  • The five-year high for Notes Payables was $2.1 million in Q2 2015, with the low at $23289.0 in Q2 2018.
  • Median Notes Payables over the past 5 years was $915897.5 (2014), compared with a mean of $967035.4.
  • The sharpest move saw Notes Payables surged 546.71% in 2014, then tumbled 96.12% in 2018.
  • Year by year, Notes Payables stood at $816776.0 in 2014, then surged by 34.68% to $1.1 million in 2015, then crashed by 36.36% to $700000.0 in 2016, then crashed by 77.29% to $159000.0 in 2017, then crashed by 85.35% to $23289.0 in 2018.
  • According to Business Quant data, Notes Payables over the past three periods came in at $23289.0, $100000.0, and $159000.0 for Q2 2018, Q1 2018, and Q4 2017 respectively.